AU2021365611A1 - B and t lymphocyte attenuator (btla) modulators and method of using same - Google Patents

B and t lymphocyte attenuator (btla) modulators and method of using same Download PDF

Info

Publication number
AU2021365611A1
AU2021365611A1 AU2021365611A AU2021365611A AU2021365611A1 AU 2021365611 A1 AU2021365611 A1 AU 2021365611A1 AU 2021365611 A AU2021365611 A AU 2021365611A AU 2021365611 A AU2021365611 A AU 2021365611A AU 2021365611 A1 AU2021365611 A1 AU 2021365611A1
Authority
AU
Australia
Prior art keywords
btla
seq
binding agent
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021365611A
Other languages
English (en)
Other versions
AU2021365611A9 (en
Inventor
Jean da Silva CORREIA
Martin Edward DAHL
Marilyn Kehry
Stephen PARMLEY
Morena SHAW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Tracks Biotherapeutics Inc
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of AU2021365611A1 publication Critical patent/AU2021365611A1/en
Publication of AU2021365611A9 publication Critical patent/AU2021365611A9/en
Assigned to First Tracks Biotherapeutics, Inc. reassignment First Tracks Biotherapeutics, Inc. Request for Assignment Assignors: ANAPTYSBIO, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2021365611A 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same Pending AU2021365611A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105067P 2020-10-23 2020-10-23
US63/105,067 2020-10-23
US202163192984P 2021-05-25 2021-05-25
US63/192,984 2021-05-25
PCT/US2021/056289 WO2022087441A2 (en) 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (2)

Publication Number Publication Date
AU2021365611A1 true AU2021365611A1 (en) 2023-06-08
AU2021365611A9 AU2021365611A9 (en) 2025-03-13

Family

ID=78695822

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021365611A Pending AU2021365611A1 (en) 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same

Country Status (9)

Country Link
US (1) US20230391872A1 (enExample)
EP (1) EP4232480A2 (enExample)
JP (1) JP2023546713A (enExample)
KR (1) KR20230096024A (enExample)
AU (1) AU2021365611A1 (enExample)
CA (1) CA3196493A1 (enExample)
IL (1) IL302135A (enExample)
MX (1) MX2023004633A (enExample)
WO (1) WO2022087441A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2007001459A2 (en) * 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CN114585416B (zh) * 2019-04-01 2025-01-17 莱克制药股份有限公司 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体
AU2023259623A1 (en) * 2022-04-27 2024-11-21 First Tracks Biotherapeutics, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same

Also Published As

Publication number Publication date
WO2022087441A3 (en) 2022-08-25
CA3196493A1 (en) 2022-04-28
JP2023546713A (ja) 2023-11-07
AU2021365611A9 (en) 2025-03-13
EP4232480A2 (en) 2023-08-30
KR20230096024A (ko) 2023-06-29
US20230391872A1 (en) 2023-12-07
IL302135A (en) 2023-06-01
WO2022087441A2 (en) 2022-04-28
MX2023004633A (es) 2023-05-12

Similar Documents

Publication Publication Date Title
JP7212098B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
US20180051082A1 (en) Antibodies directed against programmed death-1 (pd-1)
US20220235132A1 (en) Pd-1 agonist and method of using same
US20250282872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
US20230391872A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
EA053216B1 (ru) Модуляторы в- и т-лимфоцитарных аттенюаторов (btla) и способ их применения
HK40093375A (en) B and t lymphocyte attenuator (btla) modulators and method of using same
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
EA050223B1 (ru) Агонист pd-1 и способ его применения

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: FIRST TRACKS BIOTHERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): ANAPTYSBIO, INC.